Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Ron Bache
AddedFeb 13, 2024
UpdatedMay 31, 2026
Ron Bache

Ron Bache

Board Member, Viseon

LinkedInThe Org

Ron Bache's Career

Viseon
Viseon

Irvine, CA, US

Board Member· Board
Ablative Solutions
Ablative Solutions

Kalamazoo, MI, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Ron Bache's Career

Viseon
Viseon
Series B$23M402017Irvine, CA, US
Board Member· Board

Leadership at Viseon

Jeffrey ValkoJeffrey ValkoCEO
Lisa ZindelLisa ZindelCo-Founder
Alex ThomsonAlex ThomsonCo-Founder

Similar to Viseon

VisionScope TechnologiesVisionScope TechnologiesConcord, MA, USMedical Devicesest. 2007VisionScope TechnologiesConcord, MA, US · est. 2007

VisionScope Technologies provides real-time HD imaging for joint diagnosis, enhancing patient outcomes and provider efficiency.

Series A · $10.3M11
Minimus SpineMinimus SpineAustin, TX, USMedical Devicesest. 2006Minimus SpineAustin, TX, US · est. 2006

Minimus Spine: Innovating spinal health with advanced ozone injection technology.

Pre-Seed · $2M9
Vertebral TechnologiesVertebral TechnologiesMinnetonka, MN, USMedical Devicesest. 2005Vertebral TechnologiesMinnetonka, MN, US · est. 2005

Vertebral Technologies: Innovating implantable spinal devices for advanced medical solutions.

Series B · $8.6M25
Ablative Solutions
Ablative Solutions
Series D$201.8M392011Kalamazoo, MI, US
Board Member· Board

Leadership at Ablative Solutions

Dean KereiakesDean KereiakesBoard Member
Kate RumrillKate RumrillBoard Member
Tim FischellTim FischellCo-Founder
David FischellDavid FischellCo-Founder
Maurice BuchbinderMaurice BuchbinderBoard Member

Similar to Ablative Solutions

Micro Medical SolutionsMicro Medical SolutionsWilmington, MA, USMedical Devicesest. 2013Micro Medical SolutionsWilmington, MA, US · est. 2013

Micro Medical Solutions develops microvascular intervention therapies for peripheral artery disease.

Series B · $27.2M11
Corveus MedicalCorveus MedicalHouston, TX, USMedical Devicesest. 2021Corveus MedicalHouston, TX, US · est. 2021

Corveus Medical: Innovating catheter-based nerve ablation for heart failure treatment.

Pre-Seed · $500k3
Traverse VascularTraverse VascularSolana Beach, CA, USMedical Devicesest. 2019Traverse VascularSolana Beach, CA, US · est. 2019

Traverse Vascular: Innovating chronic total occlusions treatment with breakthrough medical devices since 2019.

Pre-Seed · $1.1M1
AblaconAblaconWheat Ridge, CO, USMedical Devicesest. 2015AblaconWheat Ridge, CO, US · est. 2015

Ablacon offers AI-guided therapies for atrial fibrillation, using innovative EGF™ mapping technology.

Series B · $63.5M29

Ron Bache's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Ron Bache

James MentzJames MentzCEO · BacchJustin GillJustin GillFounder · Bachan'sJay NewmanJay NewmanFounder · BachxGreg RameyGreg RameyCo-Founder · BachRon WatsonRon WatsonBoard Member · DobbyVernon AltmanVernon AltmanBoard Member · Bain & Company